Clinical Trial Search

Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability

Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants

Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants

Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants

Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants

Primary: Central Nervous System (CNS) Toxicity — 1 participants

Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05

Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants

Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…

Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…

Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants

Primary: 1-year Overall Survival (OS) — 80 percentage of participants

Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037

Primary: Progression-free Survival (PFS) Rate at 6 Months — 19 percentage of participants

Primary: Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 — 2.8 percentage of participants

Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…

Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants

Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…

Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…